The ruthenium (II) 
Introduction
The success of cisplatin (cis-Pt(NH 3 ) 2 Cl 2 ) as a chemotherapeutic agent (1) has led to the development of other complexes of platinum, as well as complexes of ruthenium as potential anticancer agents (2) (3) (4) . Ruthenium complexes have similar substitution kinetics but differ in biologic reactivity and toxicities in vivo (2-4). To date, there are no ruthenium-based anticancer drugs in routine clinical use; however, imidazolium [trans-imidazoledimethylsulfoxide-tetrachlororuthenate (III)] (NAMI-A) and indazolium [trans-tetrachlorobis(1H-indazole) ruthenate(III)] (KP1109) have advanced to clinical trials (5) (6) (7) (8) .
Most of the success to date with ruthenium-based compounds has been with complexes bearing one or more labile ligands which, like cisplatin, allow the metal to directly bind with biologic targets, particularly DNA.
NAMI-A, KP1109, and the antitumor agents [cis-bis(acetonitrile)-1,10-phenanthroline-2-phenylpyridineruthenium(II)] hexafluorophosphate (RDC11) and rutheniumaryl-X complexes (9, 10) all contain at least one labile ligand and it is postulated that these complexes directly bind biologic targets upon loss of this ligand in vivo.
The biologic activity of coordinately saturated ruthenium (II) polypyridyl complexes (RPC's), such as the trisphenanthroline complex (1 2þ ; Fig. 1 ), was extensively studied by Dwyer and Schulman (11) in the 1950s and 1960s and even before that by Beccari in the late 1930s (12) . These complexes differ from cisplatin and ruthenium complexes such as NAMI-A and KP1109 in that the ruthenium (II) ion lacks labile ligands and cannot directly form bonds with biologic targets. Instead, early studies with radiolabeled [ 106 Ru(phen) 3 ] 2þ showed that the intact complex cation was the bioactive unit, that this complex was not metabolized in vivo and did not accumulate in any organ, and that nearly all the complex was recovered in the urine (13) . Despite this lack of reactivity in vivo, these RPCs were shown to possess biologic activity both in vitro and in vivo (13) (14) (15) (16) .
RPC 1 2þ is modestly cytotoxic (IC 50 $ 90 mmol/L) with enhanced cytotoxicity generally observed by increasing the lipophilicity of the complex (17) . The 3,4,7,8-tetramethyl-1,10-phenanthroline derivative of 1 2þ was among the most cytotoxic of the derivatives found and was shown to inhibit the growth of dispersed tumor cells (Landshultz ascites) in mice (14) . Since these early studies, there have been numerous studies exploring the DNAbinding activity of RPCs (18) and to a lesser extent the cytotoxicity of RPCs (19) (20) (21) (22) (23) ; however, the anticancer activity of these complexes in vivo has not been extensively studied. The paucity of follow-up studies is due, in part, to their observed neurotoxicity, as 1 2þ has been shown to be a competitive inhibitor of acetyl cholinesterase both in vitro and in vivo (13, 24, 25) . As a consequence, the minimum lethal doses of 1 2þ (iodo salt) in mice is 12 mmol/kg when administered by intraperitoneal (i.p.) injection. A study of the peak ruthenium blood concentrations showed that RPCs able to diffuse quickly through tissue and enter the bloodstream were more neurotoxic than those slower to do so and that by increasing the complex lipophilicity it was possible to ameliorate the neurotoxicity (13) . Interestingly, 1 2þ is nontoxic when administered orally (11) .
It has been possible to track the intracellular distribution of many of these RPCs due to their inherent luminescence with both the nucleus and mitochondria often showing significant accumulation (19, 22, (26) (27) (28) . As many RPCs have been shown to bind DNA, it is often assumed that this is the biologic target (29) , although the mitochondria (19, 25, 30) and the cell-cell interface (20, 31) are also potential targets. In general, these RPCs bind to duplex DNA via electrostatic and intercalative modes but usually they do not damage DNA unless an external factor, such a light irradiation, is introduced (32, 33) . 2 ] 4þ (2 4þ ; see Fig. 1 for the structures of dppz, tpphz, and 2 4þ ) are neither reduced nor do they exhibit any DNA cleavage activity. We postulated that the redox activity of the RPC, 4 4þ , was responsible for the DNA cleavage activity and that the cleavage activity may be useful therapeutically. Moreover, the inverse sensitivity to the dioxygen concentration could enhance the cleavage activity in hypoxic tumors. Finally, we reasoned that the increased size and lipophilicity of 4 4þ and the related mononuclear complex, [(phen) 2 Ru(tatpp)]Cl 2 (3 2þ ) may ameliorate any neurotoxic side effects of these complexes in vivo. Herein, we evaluate 3 2þ and 4 4þ as potential anticancer agents in a preclinical study.
Materials and Methods

Abbreviations, stereochemistry, and nomenclature
The ruthenium complexes, [ , and 4 4þ and chloride anions. These complex cations, collectively identified as RPCs, are composed of Ru(II) ions bound to 1,10-phenanthroline (phen), tpphz, and/or (tatpp) polypyridyl ligands (Fig. 1) . If the counterion is not explicitly listed, it can be assumed to be chloride. All of the complexes are chiral (D or L) due to the 3-fold helical chirality at the ruthenium centers where the descriptor D or L is used to indicate right-or left-handed chirality, respectively, at the ruthenium centers. Typically, these complex cations are isolated as a racemic mixture for the monomers ( (40), were prepared previously described. Enantiopurity was ascertained using chiral HPLC as described (35) and was 97% or more for all complexes.
DNA cleavage assay
DNA cleavage was carried out as previously described (34) . Briefly, RPC was added to a reaction mixture containing 7 mmol/L sodium phosphate (pH 7.0) and pUC18 DNA (0.1 mg/mL). For reactions with GSH present, its concentration was 5.0 mmol/L. The reaction was quenched by addition of 2 mL sodium acetate (pH 5.2) and 80 mL ethanol and incubated at À20 C to complete precipitation. The DNA was pelleted, air-dried, resuspended in 15 mmol/L Tris-HCl, pH 8.0, 0.3 mmol/L EDTA, 3% glycerol, and 0.1% w/v bromophenol blue, and subjected to horizontal slab agarose (1%) gel at 80 V for 90 minutes with the gel immersed in TAE/0.2 mmol/L ethidium bromide. Results were visualized and recorded by using a UVPGDS 8000 gel analysis system. For studies under anaerobic conditions, all reagent solutions were degassed using N 2 . DNA stock was degassed using 5 freeze-pump-thaw cycles under N 2 . Degassed reagents were taken into an N 2 glove box and all the solutions were prepared inside it to minimize further contamination with oxygen. DMSO and TEMPO were added inside the glove box where the assays were completed and reactions quenched by precipitating the DNA using 2 mL of degassed sodium acetate at pH 5.2 and 80 mL degassed ethanol under N 2 .
Cell lines and cultures
Human non-small cell lung cancer (NSCLC) cell lines H358 (bronchioalveolar), H226 (squamous cell carcinoma), human aortic vascular smooth muscle cells, and human umbilical vascular endothelial cells (HUVEC) were obtained and maintained as previously described (41) .
Cytotoxicity assays
Cell viability and density was measured by counting trypan blue dye excluding cells in a hemocytometer, and 2 Â 10 4 viable cells in respective full culture media were placed into each well of a 96-well plate and allowed to grow at 37 C for 24 hours before addition of RPCs. After 96-hour incubation, MTT assay was conducted as previously described (41) . Non-hypoxic/hypoxic cytotoxicity. H358 cells were plated in 60 Â 15 mm 2 cell dishes with equal cell densities, respectively. Ten dishes were used per compound being tested; 5 dishes for normoxic and 5 dishes for hypoxic. Before assay, each 5-set dishes were washed with PBS and media changed with 3 mL aliquot of compound solution and put into incubators (normoxic was monitored at 5% CO 2 and 18% O 2 and hypoxic was monitored at 5% CO 2 and 1% O 2 ) accordingly. Cells were left in both incubator conditions for 24 hours, and every 4 hours, cells were checked for viability. Cytotoxicity of cells was determined by cell count with hemocytometer w/Trypan blue staining.
In situ caspase-3 assay for apoptosis. Normal (HUVEC) and lung cancer (H358) cells (0.1 Â 10 6 ) were plated on glass cover slip in tissue culture-treated 12-well plates and incubated with either 10 mmol/L of D-3 2þ or DD-4 4þ for 12 h at 37 C. Apoptotic cells were detected by staining with 5 mmol/L Caspase FITC-VAD-FMK (Promega) in situ marker for 30 minutes in the dark. The slides were rinsed with PBS and fixed with 4% paraformaldehyde for 30 minutes and mounted in a medium containing DAPI (1.5 mg/mL). Images were taken on Olympus Provis AX70 fluorescence microscope. Photographs taken at identical exposure at Â40 magnification are presented.
Effect of Ru compounds on apoptosis by TUNEL assay. Normal (HUVEC) and lung cancer (H358) cells were grown on coverslips. For Ru-compounds treatment, cells were incubated with 10 mmol/L either D-3 2þ or DD-4 4þ before TUNEL assay using Promega fluorescence detection kit according to the protocol provided by the manufacturer. Slides were analyzed by fluorescence microscope (Olympus Provis AX70). Photographs taken at identical exposure at Â40 magnification are presented. Apoptotic cells showed green fluorescence.
Animal studies
All animal experiments were carried out in accordance with a protocol approved by the Institutional Animal Care and Use Committee. Hsd: Athymic nude nu/nu mice were obtained from Harlan. C57 BL/6 mice were obtained from Harlan. The maximum tolerable dose (MTD, mg complex/kg mouse) was determined in 10-week-old male mice (3 per group) treated with 100 mL (i.p. injection) of RPCs at 6 concentrations ranging from 1 to 50 mg/mL. MTD was defined as the dose level causing no deaths or morbidity. For lung cancer xenograft studies, H358 NSCLC cells (1 Â 10 6 /mL PBS) were injected into the flanks of 10-week nu/nu mice, Harlan, followed 14 days later by i.p. injection of RPCs in 100 mL PBS. Animals were examined daily for signs of distress and tumors were measured in 2 dimensions using Vernier calipers (41) . For statistical analysis, the mean tumor volume data versus time for the 2 RPC-treated groups were combined to a single group with n ¼ 6 and a control group. A repeated-measures ANOVA analysis of the treated and control group data was obtained using the SAS programmer PROC MIXED program.
Results
Cytotoxicity
The IC 50 data from initial screening studies of antineoplastic activity of a series of RPCs were conducted in 2 NSCLC cell lines, H358 and H226 ( ), the IC 50 also appears to be a weighted average of the IC 50 values for individual diastereomers. Interestingly, the IC 50 for meso-diastereomer, DL-4 4þ , was not significantly different from the LL diastereomer, indicating that both chiral centers must be D to achieve a significant biological effect.
As shown in Fig. 2A , the cytotoxicity of D-3 2þ is enhanced when the H358 cells were incubated under hypoxic conditions (1%O 2 ) relative to normoxic conditions. This figure also includes the data from 2 controls, cisplatin and [Ru(phen) 2 (dppz)] 2þ , neither of which showed significant potentiation under hypoxic conditions. Significantly, D-3 2þ and DD-4 4þ are notably more cytotoxic toward malignant cell lines as the IC 50 values for normal HUVECs and HUVSMCs are around 100 mmol/L, an approximate 10-fold difference in cytotoxicity. This selectivity is also observed in the caspase-3 and TUNEL assays (Fig. 2C ) and appears to be unique to the tatpp-based complexes. Dwyer and colleagues found little selectivity in the cytotoxicity of RPCs such as 1 2þ or its tetramethylphenanthroline derivative toward malignant, adult, embryonic, epithielial, and fibroblastic cells (11) .
DNA cleavage by D-3
2þ and DD-4 4þ under aerobic and anaerobic conditions
As the above studies indicated that D-3 2þ and DD-4 4þ were the most active compounds, sufficient amounts of these were synthesized, purified, and authenticated for further studies. We have previously shown that the reduced form of the di-ruthenium compound 4 4þ shows hypoxia-sensitive DNA cleavage and that this reduced complex is readily formed via addition of common agents such GSH or ascorbic acid (34) . The data presented here in Fig. 2 confirmed similar activity of the mono-ruthenium complex, D-3 2þ . Supercoiled plasmid DNA was incubated with D-3 2þ and DD-4 4þ in the presence or absence of GSH and O 2 . In this assay, the conversion of supercoiled plasmid DNA to the circular form is used to monitor singlestrand cleavage events using agarose gel electrophoresis. As can be seen in Fig. 3A , RPCs D-3 2þ and DD-4 4þ only show DNA cleavage when GSH is present (lanes 4, 5, 7, 8) and this cleavage is appreciably enhanced when O 2 is absent (lanes 5 and 8, respectively). As shown in Fig. 3B , RPC D-3 2þ was also incubated with DNA in the presence of GSH and the oxygen radical scavenger DMSO (42) and the carbon and metal centered radical scavenger TEMPO (42) under anaerobic conditions. As seen in lane 4 (Fig. 3B) , there is an extensive amount of DNA cleavage upon treatment with D-3 2þ and GSH under anaerobic conditions. Addition of DMSO did not affect this cleavage activity (lane 6), whereas addition of TEMPO (lane 5) appreciably attenuated the cleavage, supporting a carbon-based radical intermediate, and ruling out any significant role for reactive oxygen species. The activity is indeed unique in comparison with transition metal-mediated DNA modification by cisplatin, which is inhibited by GSH (43) . Having shown DNA-cleaving activity, both compounds were submitted to the DTP for NCI-60 panel screening.
Spectrum of activity and predicted mechanism of action
The NCI-60 panel single dose cytotoxicity (10 mmol/L) screen for compounds D-3 2þ and DD-4 4þ conducted by the DTP revealed that RPC D-3 2þ is more cytotoxic than DD-4 4þ (mean growth percentages of 42% and 80%, respectively, for the whole panel). RPC D-3 2þ was subsequently selected for the 5-dose screen. RPC D-3 2þ showed some its best activity against leukemia, colon cancer, lung cancer and melanoma cell lines. Interestingly, the 5-dose assay predicted a unique and complex mechanism (Table 2) , a cross between the antimitotic agent paclitaxel (corr. 0.909), the RNA/DNA antimetabolite pyrazofurin (corr. 0.666), the Topo II inhibitor, dibenzyldaunomycin (corr. 0.515), and multiple alkylating agents (corr. 0.4-0.5). It is useful to note that there are no alkylating moieties in the complex and no chemical evidence of its behavior as an alkylating agent. These observations are consistent flow cytometry studies showing a marked G 2 -M block (see Fig. 2B ). Similar degree of specific G 2 block was seen with paclitaxel, an agent that does not directly cause DNA fragmentation, but does activate intrinsic apoptosis through bcl2. Some similarity in mechanism to other tubulin-binding drugs that also activate bcl2 agents that cause single (most alkylating agents) or double-stranded DNA breaks (radiation, intercalating agents) also typically cause G 2 arrest. These findings concur with the known subcellular localization of these compounds in the nucleus and mitochondria, and with previous studies of RPC . The ruthenium concentration in the whole cells and nucleus level off and were essentially equal at 30 mg RPC/mg for D-3 2þ and 18 mg RPC/mg for DD-4 4þ after 24 hours and remain this way for 72 hours.
Spectrum of activity and mechanism of cell death
The activity predicted by the NCI-60 panel toward NSCLCs was confirmed in further studies showing significant activity in NSCLCs (see Fig. 2 ). Cell-cycle analysis indicated that RPC D-3 2þ caused a profound G 2 block, characteristic of DNA fragmenting agents such as radiation and anthracyclines, but also paclitaxel, which does not directly cause DNA fragmentation.
Caspase-3 activation, PARP-cleavage, and TUNEL positivity in immunohistochemistry was observed upon treatment of H358 with RPCs confirming an increase in the percentage of cells in early and late apoptosis. In contrast, similar treatment of HUVECs or HUVSMCs with RPCs D-3 2þ or DD-4 4þ did not show apoptosis, consistent with the lesser degree of cytotoxicity observed against these cell lines. Simultaneous cytochrome c release and caspase-8 activation in H358 cells indicated that both intrinsic and extrinsic pathways are activated. Treatment with either D-3 2þ or DD-4 4þ caused a generalized decrease in kinase signaling (Fig. 2D) , with reduction in pAKT, pEGFR, PI3K, pRb, CDK4, cyclinB1, and bcl2. Bax was significantly increased by DD-4
4þ , but less so by D-3 2þ , perhaps a reason for its greater efficacy. 
Animal toxicity in mouse
MTD determinations were conducted with 1 2þ , 2
4þ and the individual stereoisomers of 4 4þ . As seen in Table 3 , it was clear that the compounds containing the tatpp ligand, 3 2þ and 4 4þ , were significantly less toxic relative to the others, with the tetracationic complex 2 4þ exhibiting the greatest toxicity. The single rutheniumtatpp complex 3 2þ (MTD, 65 mmol/kg) was the least toxic, but comparable with the MTD found for the diastereotopic mixture of the di-ruthenium complex 4 4þ (MTD 43 mmol/Kg), it was equitoxic with the DD-4 4þ enantiomer (64 mmol/kg). Interestingly, the toxicity does not seem to correlate with the complex overall charge or size. Complexes 2 4þ and 4 4þ differ little in charge or size but exhibit significantly different toxicities (MTD, 2.5 vs. 43 mmol/kg, respectively). Among the stereoisomers of 4 4þ , the DD-enantiomer exhibited the least cytotoxicity and was equitoxic with 3 2þ . From these data and the cytotoxicity studies, it is clear that there is some benefit in working with DD-4 4þ and D-3 2þ both in terms of efficacy and in lessened animal toxicity, which is consistent with earlier studies on D-1 2þ and L-1 2þ (13) . Mice receiving lethal doses were observed to display lethargy, hind limb paralysis, and respiratory distress shortly after i.p. injection.
These symptoms are associated with neurotoxicity which has been reported in earlier studies of 1 2þ (13) . Mice showing no abnormal symptoms 15 minutes after i.p. injection were generally fine thereafter.
Growth inhibition of H358 NSCLC in a nude mouse xenograft model
Tumor-bearing animals with established subcutaneously implanted H358 tumors $40 mm 2 were treated on days 0, 15, and 30 by i.p. injection containing 1 mg ($50% of MTD) RPC (D-3Cl 2 or DD-4Cl 4 ) in 100 mL PBS or PBS alone. As seen in Fig. 4 , rapid and near linear growth in tumor volume was seen in the control group. The treated groups initially showed similar tumor growth to the control, but after day 6, tumor growth slowed and only gradually increased over the remaining course of the experiment. Notably, the 2 treated groups show nearly identical behavior with the D-3 2þ -treated group showing slightly less tumor growth than the DD-4 4þ group. For statistical purposes, the 2 treated groups were combined (n ¼ 6), and using a mixed The DTP COMPARE Analysis uses cytotoxicity data for the test drug across the NCI-60 spectrum of cell lines to determine a correlation coefficient of measurement of the similarity in cytotoxic mechanism between the test subject drug and known cytotoxic drugs with known mechanisms of action. The correlation coefficient ranging from 0 to 1 reflects the degree of similarity. Thus, the above findings indicate maximum similarity of mechanism to paclitaxel and significant similarity to several drugs across the antimetabolite and alkylating agent class.
linear model to fit the data, the equality of the group means was tested using a repeated measures ANOVA analysis. Results indicate that the main group effect, the main time effect, and their interaction terms are all very significant (P < 0.00001). If we consider the divergence of the combined treated (n ¼ 6) and control (n ¼ 3) groups by day 14, 1 day before the second drug dose was administered, the MTV of the treated group is 35% that of the control group. By 32 days, all control animals had died or were sacrificed for tumors > 150 mm 2 . Tumors in the treated group were only 20% the size of the control group at that time (P < 0.0001). The last treatment was given on day 30 and, as can be seen in Fig. 4 , no further tumor growth was seen in either treated group over the next 30-day period. Survival was also improved, with 0 alive at 32 days for control, 2 of 3 and 2 of 3 alive at 60 days with both D-4 2þ and DD-3 4þ , respectively. Ruthenium-treated mice had weight gain comparable with non-tumor-bearing controls (Fig. 4) .
Discussion
These studies are the first demonstration of in vivo anticancer activity of systemically administered RPCs (lacking labile ligands) in NSCLCs. 2þ ) in terms of efficacy and selectivity for inducing apoptosis in cultured NSCLC cell lines, causing a specific G 2 -M arrest, and triggering apoptosis through both intrinsic and extrinsic pathways. Most significantly, they show statistically significant tumor growth repression (P < 0.0001) in vivo and a doubling of survival time, as shown in Fig. 4 .
By far, the most important feature discovered was the enhanced biologic activity associated with use of tatpp ligand ( Figure 4 . Effect of ruthenium compounds on H358 human lung cancer nude mice xenograft model. Hsd: Athymic nude nu/nu mice were obtained from Harlan. All animal experiments were carried out in accordance with a protocol approved by the Institutional Animal Care and Use Committee. Nine 10-week-old nude mice were divided into 3 groups of 3 animals treated with PBS (pink), ruthenium compound D-3Cl2 (green), and DD-4Cl 4 (blue). All 9 animals were injected with 1 Â 10 6 human lung cancer cells (H358) suspensions in 100 mL of PBS, subcutaneously into one flank of each nu/nu nude mouse. At the same time, animals were randomized; treatment groups as indicated in the figure. Treatment was administered when the tumor surface area exceeded $42 mm 2 . Treatment consisted of D-3 2þ (2 mg) and DD-4 4þ (2 mg) in 200 mL PBS. Control groups were treated with 200 mL PBS. Animals were examined daily for signs of tumor growth. Tumors were measured in 2 dimensions using calipers. Photographs of animals were taken at days 1, 10, 20, 30, and 60 after treatment and are shown for all groups. potentials negative of À0.70 V or more (18, 33 , are known to bind DNA via intercalation (18) , the tatpp carbon radical in the reduced species is in intimate contact with the DNA. We hypothesize H-atom abstraction from the deoxyribose unit as the likely mechanism of DNA damage. Dioxygen can react with this tatpp radical species to reform the tatpp complex (46) , are actively transported into MCF-7 cells in a nonendocytotic but temperature-dependent manner (22) . If 3 2þ and 4 4þ similarly undergo active transport, the differences in the transport pathways in malignant cells versus normal cells could explain the selectivity. Not only are the tpphz dimers actively transported, but also were observed to localize in the nucleus as shown by fluorescence and co-localization with another nuclear stain, DAPI. Complexes 3 2þ and 4 4þ are not luminescent but given the observed detection of ruthenium in the nucleus and the similarity of their structure to [(bpy) 2 Ru(tpphz)Ru(bpy) 2 ] 4þ , it is reasonable that they exhibit the same transport and localization properties as the tpphz RPCs (22) . The important difference between these 2 classes of RPCs (tatpp-vs. tpphz-based RPCs) is that the latter are not easily reduced, do not show any DNA cleavage activity, and are considerably less cytotoxic which only further emphasizes the importance and role of the redox-active ligand in the observed biological activity.
PBS
The analysis of the cytotoxicity of D-3 2þ and DD-4
4þ
(NSC 747949 and 747950, respectively) in the NCI-60 panel revealed unique patterns of cytotoxicity and the former had sufficient activity to proceed to multidose screening. The predicted mechanism of action by the NCI panel was found to be consistent with the known nucleotide-and mitochondrial-binding activity and DNAcleaving activity of this compound. Because an anaerobic environment is not used in the NCI-60 panel, mechanism of action is incompletely assessed; however, our cytotoxicity studies under hypoxic conditions reveal enhanced activity for D-3 2þ in H358 cells relative to those under normoxic conditions (Fig. 2A) . It is clear that these molecules bind DNA and mitochondria (19, 25, 30) strongly, cleave DNA, cause a specific G 2 -M arrest, and trigger apoptosis through both intrinsic and extrinsic pathways. Another possibility is the involvement of receptor-mediated death pathways where the TNF family of death receptors activate the initiator caspase-8 which can activate caspase-3 without involve the mitochondrial-mediated apoptosis.
In summary, we have systematically optimized structural features of RPCs, selecting features that optimize cancer-selective apoptosis in cultured NSCLC cell lines and on the basis of animal toxicity, have shown unique chemical mechanism of reductive DNA cleavage through a carbon-centered radical mechanism. Because of the ease with which the tatpp ligand can be reduced in situ, RPCs 3 2þ and 4 4þ display a unique and potentially hypoxia-selective ability to bind and cleave DNA through a carbon-centered radical mechanism. Combined these data show that RPCs, and specifically RPCs with bioreducible ligands, represent a pharmacologically favorable class of compounds with a natural selectivity for cancer cells and promising hypoxia-selective activity.
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